News Releases

Oct 31, 2022
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
Corporate
Sep 28, 2022
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
Corporate
Jun 28, 2022
Myriad Genetics Issues Inaugural Environmental, Social and Governance Report
Corporate
Jun 09, 2022
Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
Corporate
May 26, 2022
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
Corporate
May 04, 2022
Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
Corporate
May 03, 2022
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
Pipeline
Apr 28, 2022
Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022
Financial
Mar 14, 2022
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Corporate
Mar 08, 2022
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Corporate
Mar 02, 2022
Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
Corporate
Feb 16, 2022
Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022
Corporate
Feb 14, 2022
Myriad Genetics to Present at Two Upcoming Healthcare Conferences
Corporate
Jan 05, 2022
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference
Corporate
Jan 04, 2022
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service
Corporate